ImmunOs Gets Cash Injection To Advance Potential First-In-Class Cancer Agent

Swiss Biotech Banks $74m

 
• By Kevin Grogan
  
US dollars
The funds will go towards development of ImmunOs’s lead program, IOS-1002 through Phase II trials. • Source: Archive
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip